GUPPY's Valuation
Is 5127 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 5127 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 5127 (¥3240) is trading above our estimate of fair value (¥763.7)
Significantly Below Fair Value: 5127 is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 5127?
Key metric: As 5127 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is 5127's PE Ratio? | |
|---|---|
| PE Ratio | 36x |
| Earnings | JP¥347.00m |
| Market Cap | JP¥12.48b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 3.9x |
| Enterprise Value/EBITDA | 16.7x |
| PEG Ratio | 1.1x |
Price to Earnings Ratio vs Peers
How does 5127's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 26.4x | ||
8769 Advantage Risk Management | 33.5x | n/a | JP¥11.2b |
7096 StemCell Institute | 38.4x | 42.1% | JP¥16.2b |
7133 HYUGA PRIMARY CARELtd | 20.3x | n/a | JP¥8.9b |
4671 FALCO HOLDINGS | 13.3x | n/a | JP¥24.3b |
5127 GUPPY's | 36x | 33.0% | JP¥12.5b |
Price-To-Earnings vs Peers: 5127 is expensive based on its Price-To-Earnings Ratio (36x) compared to the peer average (32.2x).
Price to Earnings Ratio vs Industry
How does 5127's PE Ratio compare vs other companies in the JP Healthcare Industry?
| 0 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|
| 0 Companies | Estimated Growth | Market Cap |
|---|
Price-To-Earnings vs Industry: 5127 is expensive based on its Price-To-Earnings Ratio (36x) compared to the JP Healthcare industry average (16.8x).
Price to Earnings Ratio vs Fair Ratio
What is 5127's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 36x |
| Fair PE Ratio | 33.3x |
Price-To-Earnings vs Fair Ratio: 5127 is expensive based on its Price-To-Earnings Ratio (36x) compared to the estimated Fair Price-To-Earnings Ratio (33.3x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
FINDEX
JP¥20.5b
Offers medical systems, office systems, and Healthtech products in Japan.
3649
JP¥800.00
7D
-0.7%
1Y
-12.5%
Charm Care
JP¥40.4b
Engages in nursing care business.
6062
JP¥1,238.00
7D
2.1%
1Y
4.5%
Suzuken
JP¥383.2b
Primarily engages in the distribution of pharmaceuticals in Japan and internationally.
9987
JP¥4,936.00
7D
-2.8%
1Y
-1.8%